Immix Biopharma Investor Presentation Deck

Adverse Event Profile - NXC-201 Market Adverse Events Cytokine Release Syndrome (CRS) Day of median onset (min-max) Days of median duration (min-max) Immune cell associated Neurotoxicity (ICANS) Day of median onset (min-max) Day of median duration (min-max) Toxicity Management Tocilizumab Dexamethasone Source: Arcellx July 2022 Corporate Presentation. ICANS of any grade ARCELLX 100 x10 cells n=25 Grade 3-4 0 (0%) 2 (1-8 days) 8 (3-13 days) 6 (24%) 4.5 (3-6 days) 7.5 (4-11 days) 19 (76%) 13 (52%) ARCELLX 300x10 cells n=6 Grade 3-4 1 (17%) 2 (1-2 days) 5 (3-10 days) 1 (17%) 7 days 23 days 5 (83%) 2 (33%) ●●● S BIOPHARMA IMMIX 44

View entire presentation